According to the 2017 WHO Weekly Epidemiological Report, Egypt is the first country in the Region to receive acknowledgement of having achieved the criteria for elimination of LF as a public health problem. After passing the third and final TAS in all endemic IUs in 2016, Yemen remained in post-MDA surveillance while preparing its dossier. Sudan completed remapping surveys in 113 localities in 2017 and continued MDA in 11 of 60 endemic IUs. The population requiring MDA has decreased by 2.9 million, representing a 23% reduction. Both Egypt and Yemen have documented the burden of disease and availability of care to patients. Sudan has not reported information on morbidity, but the country initiated a new plan for MMDP, starting with the distribution of brochures on home management to all state health offices.
The treatment regime in all EMRO endemic countries is albendazole plus DEC (diethylcarbamazine).
The Eastern Mediterranean Programme Review Group, the body which reviews national programmes, applciations for drug donations, provides technical guidance and identifies operational research issues is chaired by:
National Nutrition Institute
General Organisation for Teaching Hospitals & Institutes
16 Kasr El Aini St
E: reda.mr.ramzy [at] gmail.com
See WHO Weekly Epidemiological Report for the full detailed report